Answers are grounded in this paper and cite their sources.
The rapid mutation rate of influenza viruses necessitates annual updates of vaccine formulations, underscoring the urgent need for a universal influenza vaccine. Current computationally optimized antigen strategies are mostly confined to certain subtypes and thus fail to elicit broad-spectrum immunity against heterosubtypic strains. Here, we developed the PanFlu-IOA (Pan-Influenza Iteratively Optimized Antigen) toolkit to overcome systemic bias and extract universal antigenic features across diverse evolutionary branches. Using this toolkit, we generated two universal hemagglutinin (HA) sequences G1-HA and G2-HA for influenza virus Group 1 and Group 2, respectively. These two HAs were incorporated into an mRNA-lipid nanoparticle system to construct a broad-spectrum vaccine candidate termed panFluA. In mice, panFluA elicits robust cross-reactive humoral immunity, Th1-biased systemic CD4⁺ T cell responses, and cytotoxic CD8⁺ T cell activation, while successfully establishing durable lung-resident memory T cells. Notably, panFluA conferred potent cross-protection against lethal challenges with highly divergent Group 1 and Group 2 influenza viruses. Mechanistic studies revealed that this protection was mediated by the coordinated action of humoral and cellular immunity, as confirmed by T-cell depletion and passive serum transfer experiments. Overall, panFluA induced broad immune responses against conserved HA antigens. Our study provides a general strategy for next-generation universal influlenza vaccines. Researchers developed PanFlu-IOA, a computational approach to design a broad spectrum mRNA influenza vaccine. The vaccine induced broad immune responses and protected mice against multiple influenza subtypes, offering a path to universal vaccines.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: